Otsuka and Astex announce that the European Commission has a

Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada , Norway , Iceland , Liechtenstein , Japan , Vienna , Wien , Austria , United States , Tokyo , American , Otsuka Europe , Martin Buckland , Alison Ross , Otsuka Pharmaceutical Europe Ltd , Taiho Oncology Inc , Taiho Pharmaceutical Co Ltd , Otsuka Pharmaceutical Company Ltd , European Hematology Association Congress , Otsuka Holdings Co Ltd , European Commission , American Society Of Hematology Annual Meeting , European Medicines Agency , Otsuka Pharmaceutical Co Ltd , Astex Pharmaceuticals Inc , Pharmaceutical Europe , Astex Pharmaceuticals , European Economic Area , Paediatric Investigation Plan , Median Overall Survival , Complete Response , Otsuka Pharmaceutical Company , Taiho Oncology , Practice Guidelines , Therapy Extend , Cynomolgus Monkeys , Cytidine Deaminase Inhibitor , American Society , Hematology Annual Meeting , New Orleans , Product Characteristics , Blood Cancer ,